Premium
Efficacy, cutaneous tolerance and cosmetic acceptability of desonide 0.05% lotion (Desowen ® ) versus vehicle in the short‐term treatment of facial atopic or seborrhoeic dermatitis
Author(s) -
Freeman Susanne,
Howard Anne,
Foley Peter,
Rosen Robert,
Wood Glenda,
See JoAnn,
Gray Susan
Publication year - 2002
Publication title -
australasian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.67
H-Index - 53
eISSN - 1440-0960
pISSN - 0004-8380
DOI - 10.1046/j.1440-0960.2002.00592.x
Subject(s) - lotion , medicine , clearance , dermatology , atopic dermatitis , rash , adverse effect , seborrhoeic dermatitis , seborrheic dermatitis , randomized controlled trial , surgery , pharmacology , urology
SUMMARY The differences between topical corticosteroids are based mainly on their potency, safety and patient acceptability. The aim of this study was to evaluate a mild‐ to mid‐potent topical corticosteroid, desonide 0.05%, on these three parameters in an Australian cohort of patients with facial seborrhoeic or atopic dermatitis. Eighty‐one adult patients were randomized to receive desonide 0.05% lotion or its vehicle, applied twice daily for 3 weeks under double‐blind conditions. In the active treatment group, 88% of patients had their skin condition cleared or almost cleared and only two patients experienced cutaneous adverse events (rash and pruritus). The acceptability of the lotion was high; 95% of patients stated they would use this topical corticosteroid again. These data support the short‐term use of desonide 0.05% lotion as a suitable agent for the short‐term treatment of facial dermatitis.